{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,12]],"date-time":"2026-03-12T02:33:29Z","timestamp":1773282809596,"version":"3.50.1"},"reference-count":28,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2019,11,19]],"date-time":"2019-11-19T00:00:00Z","timestamp":1574121600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2019,11,19]],"date-time":"2019-11-19T00:00:00Z","timestamp":1574121600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/501100009367","name":"Mansoura University","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100009367","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int J Clin Pharm"],"published-print":{"date-parts":[[2020,2]]},"DOI":"10.1007\/s11096-019-00940-1","type":"journal-article","created":{"date-parts":[[2019,11,19]],"date-time":"2019-11-19T02:01:12Z","timestamp":1574128872000},"page":"80-88","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":16,"title":["Extensive drug resistant Acinetobacter baumannii: a comparative study between non-colistin based combinations"],"prefix":"10.1007","volume":"42","author":[{"given":"Eman","family":"Elsayed","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0276-769X","authenticated-orcid":false,"given":"Mohamed A.","family":"Elarabi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dana A.","family":"Sherif","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mohamed","family":"Elmorshedi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Noha","family":"El-Mashad","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2019,11,19]]},"reference":[{"key":"940_CR1","unstructured":"Antibiotic \/ Antimicrobial Resistance (AR \/ AMR)\u2014About Antimicrobial Resistance. Centers for Disease Control and Prevention (CDC): U.S. Department of Health & Human Services, 2010. Retrieved 2 Sept 2019, from https:\/\/www.cdc.gov\/drugresistance\/about.html."},{"key":"940_CR2","unstructured":"Acinetobacter in Healthcare Settings\u2014General information about Acinetobacter. Centers for Disease Control and Prevention (CDC): U.S. Department of Health & Human Services, 2010. Retrieved 19 June 2018, from https:\/\/www.cdc.gov\/hai\/organisms\/acinetobacter.html."},{"issue":"3","key":"940_CR3","doi-asserted-by":"publisher","first-page":"268","DOI":"10.1111\/j.1469-0691.2011.03570.x","volume":"18","author":"AP Magiorakos","year":"2012","unstructured":"Magiorakos AP, Srinivasan A, Carey RB, Carmeli Y, Falagas ME, Giske CG, Harbarth S, Hindler JF, Kahlmeter G, Olsson-Liljequist B, Paterson DL. Multidrug-resistant, extensively drug-resistant and pandrug-resistant bacteria: an international expert proposal for interim standard definitions for acquired resistance. Clin Microbiol Infect. 2012;18(3):268\u201381.","journal-title":"Clin Microbiol Infect"},{"key":"940_CR4","volume-title":"Phenotypic and genetic characterization of multidrug resistant nosocomial isolates of acinetobacter calcoaceticus\u2013baumannii complex from intensive care units in Mansoura University main hospital","author":"NA-MMM El-Bassuony","year":"2016","unstructured":"El-Bassuony NA-MMM. Phenotypic and genetic characterization of multidrug resistant nosocomial isolates of acinetobacter calcoaceticus\u2013baumannii complex from intensive care units in Mansoura University main hospital. Mansoura: Faculty of Medicine, Mansoura University; 2016."},{"issue":"9","key":"940_CR5","doi-asserted-by":"publisher","first-page":"1333","DOI":"10.1086\/429323","volume":"40","author":"ME Falagas","year":"2005","unstructured":"Falagas ME, Kasiakou SK. Colistin: the revival of polymyxins for the management of multidrug-resistant gram-negative bacterial infections. Clin Infect Dis. 2005;40(9):1333\u201341.","journal-title":"Clin Infect Dis"},{"issue":"9","key":"940_CR6","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1016\/S1473-3099(06)70580-1","volume":"6","author":"J Li","year":"2006","unstructured":"Li J, Nation RL, Turnidge JD, et al. Colistin: the re-emerging antibiotic for multidrug-resistant Gram-negative bacterial infections. Lancet Infect Dis. 2006;6(9):589\u2013601.","journal-title":"Lancet Infect Dis"},{"issue":"9","key":"940_CR7","doi-asserted-by":"publisher","first-page":"816","DOI":"10.1111\/j.1469-0691.2008.02061.x","volume":"14","author":"N Petrosillo","year":"2008","unstructured":"Petrosillo N, Ioannidou E, Falagas ME. Colistin monotherapy vs. combination therapy: evidence from microbiological, animal and clinical studies. Clin Microbiol Infect. 2008;14(9):816\u201327.","journal-title":"Clin Microbiol Infect"},{"issue":"4","key":"940_CR8","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1016\/j.diagmicrobio.2005.03.003","volume":"52","author":"CR Kiffer","year":"2005","unstructured":"Kiffer CR, Sampaio JL, Sinto S, et al. In vitro synergy test of meropenem and sulbactam against clinical isolates of Acinetobacter baumannii. Diagn Microbiol Infect Dis. 2005;52(4):317\u201322.","journal-title":"Diagn Microbiol Infect Dis"},{"key":"940_CR9","first-page":"32","volume-title":"Performance standards for antimicrobial susceptibility testing. CLSI Supplement M100","author":"CLSI","year":"2017","unstructured":"CLSI. Performance standards for antimicrobial susceptibility testing. CLSI Supplement M100, vol. 37. 27th ed. Wayne: Clinical and Laboratory Standards Institute; 2017. p. 32\u20139.","edition":"27"},{"key":"940_CR10","first-page":"46","volume-title":"Performance standards for antimicrobial susceptibility testing. CLSI Supplement M100","author":"CLSI","year":"2017","unstructured":"CLSI. Performance standards for antimicrobial susceptibility testing. CLSI Supplement M100, vol. 37. 27th ed. Wayne: Clinical and Laboratory Standards Institute; 2017. p. 46\u20139.","edition":"27"},{"key":"940_CR11","unstructured":"TYGACIL (tigecycline)\u2014FDA [PDF file]. FDA Reference ID. 3379756. Philadelphia, PA 19101: Wyeth Pharmaceuticals Inc., 2013., Retrieved 13 March 2018 from https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2013\/021821s026s031lbl.pdf."},{"key":"940_CR12","unstructured":"Zeina A, Kanafani M, Souha S, Kanj MD. Acinetobacter infection: treatment and prevention. UpToDate: Wolters Kluwer Clinical Drug Information, Inc., 2018. Retrieved 21 March 2018, from\u00a0https:\/\/www.uptodate.com\/contents\/acinetobacter-infection-treatment-and-prevention."},{"issue":"6","key":"940_CR13","doi-asserted-by":"publisher","first-page":"1369","DOI":"10.1093\/jac\/dkn128","volume":"61","author":"MS Oliveira","year":"2008","unstructured":"Oliveira MS, Prado GV, Costa SF, Grinbaum RS, Levin AS. Ampicillin\/sulbactam compared with polymyxins for the treatment of infections caused by carbapenem-resistant Acinetobacter spp. J Antimicrob Chemother. 2008;61(6):1369\u201375.","journal-title":"J Antimicrob Chemother"},{"issue":"2","key":"940_CR14","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1016\/j.ijantimicag.2009.02.003","volume":"34","author":"N Norskov-Lauritsen","year":"2009","unstructured":"Norskov-Lauritsen N, Marchandin H, Dowzicky MJ. Antimicrobial susceptibility of tigecycline and comparators against bacterial isolates collected as part of the TEST study in Europe (2004\u20132007). Int J Antimicrob Agents. 2009;34(2):121\u201330.","journal-title":"Int J Antimicrob Agents"},{"issue":"1","key":"940_CR15","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1086\/653120","volume":"51","author":"J Fishbain","year":"2010","unstructured":"Fishbain J, Peleg AY. Treatment of Acinetobacter infections. Clin Infect Dis. 2010;51(1):79\u201384.","journal-title":"Clin Infect Dis"},{"key":"940_CR16","first-page":"1","volume":"32","author":"L Sun","year":"2017","unstructured":"Sun L, Wang X, Li Z. Successful treatment of multidrug-resistant Acinetobacter baumannii meningitis with ampicillin sulbactam in primary hospital. Br J Neurosurg. 2017;32:1\u20134.","journal-title":"Br J Neurosurg"},{"key":"940_CR17","doi-asserted-by":"publisher","first-page":"374","DOI":"10.1186\/s12879-016-1717-6","volume":"16","author":"JJ Ye","year":"2016","unstructured":"Ye JJ, Lin HS, Yeh CF, et al. Tigecycline-based versus sulbactam-based treatment for pneumonia involving multidrug-resistant Acinetobacter calcoaceticus-Acinetobacter baumannii complex. BMC Infect Dis. 2016;16:374.","journal-title":"BMC Infect Dis"},{"key":"940_CR18","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1186\/1471-2334-14-102","volume":"14","author":"YC Chuang","year":"2014","unstructured":"Chuang YC, Cheng CY, Sheng WH, et al. Effectiveness of tigecycline-based versus colistin- based therapy for treatment of pneumonia caused by multidrug-resistant Acinetobacter baumannii in a critical setting: a matched cohort analysis. BMC Infect Dis. 2014;14:102.","journal-title":"BMC Infect Dis"},{"issue":"4","key":"940_CR19","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1016\/j.bjid.2012.10.029","volume":"17","author":"H Chu","year":"2013","unstructured":"Chu H, Zhao L, Wang M, Liu Y, Gui T, Zhang J. Sulbactam-based therapy for Acinetobacter baumannii infection: a systematic review and meta-analysis. Braz J Infect Dis. 2013;17(4):389\u201394.","journal-title":"Braz J Infect Dis"},{"key":"940_CR20","unstructured":"Antibiotic name. Lexicomp Online,Lexi-drugs online: Wolters Kluwer Clinical Drug Information, Inc., 2018.Available from: http:\/\/online.lexi.com. Subscription required to view."},{"key":"940_CR21","unstructured":"Acinetobacter in Healthcare Settings\u2014Treatment of Acinetobacter infection. Centers for Disease Control and Prevention (CDC): U.S. Department of Health & Human Services, 2010. Retrieved 19 March 2018, Retrieved from\u00a0https:\/\/www.cdc.gov\/hai\/organisms\/acinetobacter.html."},{"issue":"3","key":"940_CR22","doi-asserted-by":"publisher","first-page":"120","DOI":"10.5414\/CP203102","volume":"56","author":"Y Qin","year":"2018","unstructured":"Qin Y, Zhang J, Wu L, Zhang D, Fu L, Xue X. Comparison of the treatment efficacy between tigecycline plus high-dose cefoperazone-sulbactam and tigecycline monotherapy against ventilator-associated pneumonia caused by extensively drug-resistant Acinetobacter baumannii. Int J Clin Pharmacol Ther. 2018;56(3):120\u20139.","journal-title":"Int J Clin Pharmacol Ther"},{"issue":"1","key":"940_CR23","first-page":"11","volume":"27","author":"SF Assimakopoulos","year":"2019","unstructured":"Assimakopoulos SF, Karamouzos V, Lefkaditi A, et al. Triple combination therapy with high-dose ampicillin\/sulbactam, high-dose tigecycline and colistin in the treatment of ventilator-associated pneumonia caused by pan-drug resistant Acinetobacter baumannii: a case series study. Infez Med. 2019;27(1):11\u20136.","journal-title":"Infez Med"},{"issue":"5","key":"940_CR24","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1179\/1973947814Y.0000000203","volume":"27","author":"B Liu","year":"2015","unstructured":"Liu B, Bai Y, Liu Y, et al. In vitro activity of tigecycline in combination with cefoperazone-sulbactam against multidrug-resistant Acinetobacter baumannii. J Chemother. 2015;27(5):271\u20136.","journal-title":"J Chemother"},{"issue":"4","key":"940_CR25","doi-asserted-by":"publisher","first-page":"1119","DOI":"10.1590\/S1517-838246420140101","volume":"46","author":"F Temocin","year":"2015","unstructured":"Temocin F, Erdinc FS, Tulek N, et al. Synergistic effects of sulbactam in multi-drug-resistant Acinetobacter baumannii. Braz J Microbiol. 2015;46(4):1119\u201324.","journal-title":"Braz J Microbiol"},{"issue":"9","key":"940_CR26","doi-asserted-by":"publisher","first-page":"677","DOI":"10.1038\/ja.2014.99","volume":"67","author":"X Dong","year":"2014","unstructured":"Dong X, Chen F, Zhang Y, Liu H, Liu Y, Ma L. In vitro activities of rifampin, colistin, sulbactam and tigecycline tested alone and in combination against extensively drug-resistant Acinetobacter baumannii. J Antibiot (Tokyo). 2014;67(9):677\u201380.","journal-title":"J Antibiot (Tokyo)"},{"issue":"1","key":"940_CR27","first-page":"19","volume":"9","author":"N Madadi-Goli","year":"2017","unstructured":"Madadi-Goli N, Moniri R, Bagheri-Josheghani S, Dasteh-Goli N. Sensitivity of levofloxacin in combination with ampicillin-sulbactam and tigecycline against multidrug-resistant Acinetobacter baumannii. Iran J Microbiol. 2017;9(1):19\u201325.","journal-title":"Iran J Microbiol"},{"issue":"10","key":"940_CR28","first-page":"2296","volume":"68","author":"ST Housman","year":"2013","unstructured":"Housman ST, Hagihara M, Nicolau DP, Kuti JL. In vitro pharmacodynamics of human-simulated exposures of ampicillin\/sulbactam, doripenem and tigecycline alone and in combination against multidrug-resistant Acinetobacter baumannii. J Antimicrob Chemother. 2013;68(10):2296\u2013304.","journal-title":"J Antimicrob Chemother"}],"container-title":["International Journal of Clinical Pharmacy"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11096-019-00940-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11096-019-00940-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11096-019-00940-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,11,18]],"date-time":"2020-11-18T04:36:26Z","timestamp":1605674186000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11096-019-00940-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,11,19]]},"references-count":28,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,2]]}},"alternative-id":["940"],"URL":"https:\/\/doi.org\/10.1007\/s11096-019-00940-1","relation":{},"ISSN":["2210-7703","2210-7711"],"issn-type":[{"value":"2210-7703","type":"print"},{"value":"2210-7711","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,11,19]]},"assertion":[{"value":"30 May 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 November 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 November 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Eman Elsayed, Mohamed A. Elarabi, Dana A. Sherif, Mohamed Elmorshedi, and Noha El-Mashad declare that they have no conflicts of interest.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}}]}}